United Capital Financial Advisors LLC Invests $1.49 Million in DaVita Inc. $DVA

Posted by George Bondi on Aug 30th, 2026

United Capital Financial Advisors LLC bought a new stake in DaVita Inc. (NYSE:DVA – Free Report) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 6,680 shares of the company’s stock, valued at approximately $1,486,000.

Other institutional investors have also recently made changes to their positions in the company. Jefferies Financial Group Inc. acquired a new position in DaVita in the second quarter valued at about $687,000. Public Employees Retirement System of Ohio purchased a new position in DaVita during the 2nd quarter valued at about $2,043,000. Capstone Investment Advisors LLC acquired a new position in DaVita in the 2nd quarter valued at about $479,000. Redwood Investment Management LLC purchased a new stake in DaVita during the second quarter worth about $2,257,000. Finally, Transamerica Financial Advisors LLC acquired a new stake in shares of DaVita during the second quarter worth about $101,000. Hedge funds and other institutional investors own 90.12% of the company’s stock.

DaVita Trading Up 1.0%

Shares of DVA stock opened at $180.72 on Friday. DaVita Inc. has a twelve month low of $101.00 and a twelve month high of $247.49. The company has a market capitalization of $11.53 billion, a P/E ratio of 14.79, a price-to-earnings-growth ratio of 0.47 and a beta of 0.88. The business’s 50 day moving average is $211.96 and its two-hundred day moving average is $183.05.

DaVita (NYSE:DVA – Get Free Report) last announced its quarterly earnings results on Tuesday, August 4th. The company reported $4.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.88 by $0.14. The business had revenue of $3.55 billion during the quarter, compared to the consensus estimate of $3.50 billion. DaVita had a net margin of 6.05% and a negative return on equity of 217.63%. The business’s revenue was up 5.2% compared to the same quarter last year. During the same quarter last year, the firm posted $2.95 EPS. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. As a group, equities analysts predict that DaVita Inc. will post 14.57 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the stock. Truist Financial cut their target price on shares of DaVita from $250.00 to $215.00 and set a “hold” rating on the stock in a research note on Friday, August 7th. Barclays increased their price objective on DaVita from $218.00 to $224.00 and gave the company an “equal weight” rating in a research note on Wednesday, August 5th. TD Cowen upgraded DaVita from a “hold” rating to a “buy” rating and upped their price target for the stock from $201.00 to $220.00 in a report on Friday, August 7th. UBS Group lifted their price objective on DaVita from $235.00 to $270.00 and gave the company a “buy” rating in a research note on Friday, July 10th. Finally, Weiss Ratings raised shares of DaVita from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, August 5th. Four analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $221.75.

Get Our Latest Research Report on DVA

Insider Buying and Selling at DaVita

In other news, insider Kathleen Alyce Waters sold 15,405 shares of the company’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $208.40, for a total value of $3,210,402.00. Following the sale, the insider directly owned 109,194 shares in the company, valued at $22,756,029.60. This represents a 12.36% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 1.90% of the stock is currently owned by company insiders.

DaVita Company Profile

(Free Report)

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.